Alger Mid Cap Focus Fund on Insmed Incorporated
Thesis
Alger sees Insmed's opportunity as a combination of expanding adoption of its commercial respiratory and rare-disease products and advancing a pipeline in areas of meaningful unmet need. The stock weakened because investors questioned early Brinsupri launch quality, including patient additions, discontinuations and compliance. The fund believes better execution, greater disclosure around launch dynamics and additional data could rebuild investor confidence over time.
“we believe improved execution and additional data could help restore investor confidence over time.”
Key risks
- Brinsupri patient additions and discontinuation rates
- Compliance trends and durability of the Brinsupri launch